Page 133 - Read Online
P. 133

Page 314                                               Yasin et al. J Transl Genet Genom 2020;4:307-19  I  https://doi.org/10.20517/jtgg.2020.30

               observations below.

               Developmental delay/ID and/or ASD is a primary characteristic feature in patients with PILBOS, SNIBCPS,
               SIHIWES and ZFS  [52,54-56] . Also, 27.5% of patients with CHARGE syndrome have been reported to have
                   [59]
                                                                        [60]
               ASD , and ID is also reported in patients with CHARGE syndrome .
               Notably, in addition to neurodevelopmental and neurocognitive phenotypes such as developmental delay
               and/or ID and/or ASD, patients from all four syndromes were reported to have macrocephaly. Speech
               delays are noted for PILBOS, SNIBCPS and ZFS patients. Of other characteristic phenotypes found in ZFS
               patients, hypotonia and some facial phenotypes such as hypertelorism and low-set ears in SNIBCPS, and
               skeletal phenotypes in SIHIWES are noted. Cardiac defects are seen in SIHIWES, as they are in CHARGE
               syndrome, and they have been reported in patients with ZFS. Finally, a characteristic facial gestalt is part of
               the presentation of SIHIWES, SNIBPCS and ZFS but not of the other two syndromes.

               Due to the discovery of thus far five of the nine CHDs being disease-causing, there has been a flourishing
               of functional studies investigating pathophysiology in a number of model systems including animal and
                                                                                                       [61]
               several human cellular types. Others have comprehensively reviewed these studies for several CHDs ,
                                      [16]
                                                                        [16]
                          [29]
               for all CHDs , for CHD2 , and for CHDs in stem cell function . As these reviews are limited in their
               discussion of CHD8, we limit ourselves here to overviewing pertinent functional studies in CHD8 to fill the
               lacunae.
               Role of CHD8 in NDD
               There were only seven publications with the key word “CHD8” when it was first discovered as a causative
                                   [51]
               gene for NDDs in 2007 . In just over the dozen years since then, a further 141 publications appear with
               “CHD8” as a key word, greatly enriching our understanding of the pathogenic and functional contribution of
               this gene. We note that several of these studies support an important role for CHD8 in cancer [62,63] , which is
               beyond the scope of this paper. The burgeoning interest in CHD8 has no doubt been spurred by its reported
                                             [64]
               causation of up to 0.5% of all ASD . Extraordinarily, there are six different groups who have published
                                                                                                        [71]
               findings from mouse models alone [65-70] , as well as others who report functional studies with C. elegans
                            [72]
                                                                                            [73]
               and Drosophila , and the first functional model study results were obtained with zebrafish . Furthermore,
               a growing number of groups are exploring functional studies in human cellular models [74-77] . We will briefly
               overview the main findings from these model studies below.
               Human cellular model studies
                                                                                               [74]
               To our knowledge, the first human cellular model study was presented by Sugathan et al.  who used
               induced pluripotent stem cell-derived neural progenitor cells (NPCs) to examine CHD8 regulation
               in transcriptional networks. They knocked down CHD8 to single allele expression levels and then
               examined whole transcriptome and genome-wide ChIP-seq data to derive genome-wide impacts of the
               haploinsufficiency. They found that the expression of 1,756 genes was altered overall, with downregulated
               genes enriched for pathways involved in brain development. In addition, a total of 5,658 genes were shown to
               have possible CHD8-binding sites, and these were associated with transcriptional regulation and chromatin
               modification. These data indicate widespread downstream targeting.

               A later study examining CHD8 knockdown in commercial human NPCs derived from neuroblastoma
               cells, discovered altered expression of both protein-coding and noncoding RNA genes, with a total of 1715
                                            [77]
               genes showing altered expression . This cited study also found that the differentially expressed genes
               were enriched for neuronal development pathways and included known ASD candidate genes, similarly to
                           [74]
               Sugathan et al. .
               A separate group generated iPSC-derived NPCs from a human donor using CRISPR/Cas-9 heterozygous
                                      [76]
               gene disruption in CHD8 . They followed this by generating neurons and then brain organoids from
   128   129   130   131   132   133   134   135   136   137   138